Melphalan

Melphalan, the active ingredient in this product, is an alkylating agent presented as an intravenous formulation for use in oncology settings. It is employed to treat certain hematologic and solid tumors, most notably multiple myeloma and ovarian cancer, and is administered under strict medical supervision.

GNH USA supplies Melphalan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Melphalan is used in oncology to target malignant cells in specific blood and solid tumor indications.

- Multiple myeloma: reduces malignant plasma cell proliferation and improves survival outcomes. - Ovarian cancer: used as part of combination chemotherapy regimens to shrink tumor burden. - Autologous stem cell transplantation conditioning: provides high‑dose myeloablation to enable engraftment of transplanted stem cells.

Melphalan may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset commonly reported during treatment. - Fatigue: persistent tiredness affecting daily activities. - Myelosuppression: decreased blood cell counts leading to anemia or infection risk.

Serious or Rare Side Effects: - Severe neutropenia: markedly low neutrophil count increasing infection susceptibility. - Thrombocytopenia: low platelet levels that may cause bleeding. - Secondary malignancies: rare development of new cancers after treatment.

When using Melphalan, careful monitoring and specific safety measures are recommended.

- Monitor blood counts: perform regular CBC to detect myelosuppression. - Assess renal function: adjust therapy in patients with impaired kidneys. - Avoid use in pregnancy: teratogenic potential requires contraception for women of childbearing potential. - Use protective equipment: healthcare personnel should wear gloves and handle under a biological safety cabinet. - Conduct pre‑treatment infection screening: identify and treat active infections before initiating therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Melphalan can interact with several medicines, requiring attention to avoid harmful effects.

Major Interactions (Avoid): - Concurrent use with other alkylating agents: additive myelosuppression. - High‑dose radiation therapy: increased risk of tissue toxicity. - Live vaccines: compromised immune response may lead to infection.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., fluconazole): may increase melphalan plasma levels. - CYP450 inducers (e.g., rifampin): may reduce efficacy. - Granulocyte colony‑stimulating factor (G‑CSF): may mask bone marrow suppression.